It is very uncertain whether immunologic response to YF vaccine in HIV‐infected adults changes immunogenicity: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).
It is very uncertain whether immunologic response to YF vaccine in HIV‐infected adults changes duration: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Interleukin‐2 RA induction showed no clear difference in mortality Mortality at latest compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in infection Number of participants diagnosed with infection compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in cancer Number of participants diagnosed with cancer compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in mortality Mortality at latest compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA may leads to higher acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in infection Number of participants diagnosed with infection compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in cancer Number of participants diagnosed with cancer compared with polyclonal antibody induction (low certainty).
IL‐2 receptor antagonist induction showed no clear difference in acute rejection compared with no antibody induction (moderate certainty).
IL‐2 receptor antagonist induction showed no clear difference in bronchiolitis obliterans syndrome compared with no antibody induction (moderate certainty).
IL‐2 receptor antagonist induction showed no clear difference in mortality compared with no antibody induction (moderate certainty).
Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).